drugset / Trial / NCT00330070

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

NCT00330070 ↗

Phase 2 Completed 200 enrolled Inflazyme Pharmaceuticals Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.

Timeline

Start
2006-05
Primary completion
—
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IPL512,602 Unknown 20 mg Oral

Indications